K. Kalinsky

发表论文 282 篇 · 总被引 8270 次 · h-index 43

代表论文

Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. (2025 · Journal of Clinical Oncology · 被引 58)
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. (2026 · New England Journal of Medicine · 被引 36)
MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer (2025 · Nature Communications · 被引 16)
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. (2025 · Annals of Oncology · 被引 15)
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. (2025 · European Journal of Cancer · 被引 12)
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). (2025 · Journal of Clinical Oncology · 被引 8)